These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9304297)

  • 1. [Development and study of properties of immunoglobulins against Lassa fever].
    Krasnianskiĭ VP; Gradoboev VN; Borisevich IV; Potryvaeva NV; Lebedinskaia EV; Chernikova NK; Timan'kova GD
    Vopr Virusol; 1997; 42(4):168-71. PubMed ID: 9304297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development and study of immunoglobulins against Lassa fever].
    Krasniaskiĭ VP; Gradoboev VN; Borisevich IV; Potryvaeva NV; Lebedinskaia EV; Chernikova NK; Timan'kova GD
    Vopr Virusol; 1997; 42(2):71-4. PubMed ID: 9182403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A trial to produce an inactivated Lassa fever vaccine].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Vopr Virusol; 1993; 38(6):276-9. PubMed ID: 8303891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imported Lassa fever in Germany: surveillance and management of contact persons.
    Haas WH; Breuer T; Pfaff G; Schmitz H; Köhler P; Asper M; Emmerich P; Drosten C; Gölnitz U; Fleischer K; Günther S
    Clin Infect Dis; 2003 May; 36(10):1254-8. PubMed ID: 12746770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever].
    Firsova IV; Shatokhina IV; Borisevich IV; Evseev AA; Maksimov VA; Pantiukhov VB; Khmelev AL
    Vopr Virusol; 2003; 48(6):43-5. PubMed ID: 14708232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lassa fever. Effective therapy with ribavirin.
    McCormick JB; King IJ; Webb PA; Scribner CL; Craven RB; Johnson KM; Elliott LH; Belmont-Williams R
    N Engl J Med; 1986 Jan; 314(1):20-6. PubMed ID: 3940312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
    Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
    Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys.
    Jahrling PB; Peters CJ; Stephen EL
    J Infect Dis; 1984 Mar; 149(3):420-7. PubMed ID: 6715898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experimental Lassa infection in monkeys and its treatment with ribamidil].
    Fidarov FM; Sabynin VM; Petkevich AS; Surikova LE; Vladyko AS; Lukashevich IS
    Vopr Virusol; 1990; 35(6):504-6. PubMed ID: 2082557
    [No Abstract]   [Full Text] [Related]  

  • 10. Lassa fever: epidemiology, therapy and vaccine development.
    McCormick JB
    Kansenshogaku Zasshi; 1988 Mar; 62 Suppl():353-66. PubMed ID: 3138361
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective vaccine for lassa fever.
    Fisher-Hoch SP; Hutwagner L; Brown B; McCormick JB
    J Virol; 2000 Aug; 74(15):6777-83. PubMed ID: 10888616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
    Clegg JC; Lloyd G
    Lancet; 1987 Jul; 2(8552):186-8. PubMed ID: 2885642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current research for a vaccine against Lassa hemorrhagic fever virus.
    Warner BM; Safronetz D; Stein DR
    Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
    Marzi A; Feldmann F; Geisbert TW; Feldmann H; Safronetz D
    Emerg Infect Dis; 2015 Feb; 21(2):305-7. PubMed ID: 25625358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
    Bredenbeek PJ; Molenkamp R; Spaan WJ; Deubel V; Marianneau P; Salvato MS; Moshkoff D; Zapata J; Tikhonov I; Patterson J; Carrion R; Ticer A; Brasky K; Lukashevich IS
    Virology; 2006 Feb; 345(2):299-304. PubMed ID: 16412488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.
    Cross RW; Mire CE; Branco LM; Geisbert JB; Rowland MM; Heinrich ML; Goba A; Momoh M; Grant DS; Fullah M; Khan SH; Robinson JE; Geisbert TW; Garry RF
    Antiviral Res; 2016 Sep; 133():218-222. PubMed ID: 27531367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some tolerance for fur--animal studies in PLoS Medicine.
    The
    PLoS Med; 2005 Jun; 2(6):e203. PubMed ID: 15971961
    [No Abstract]   [Full Text] [Related]  

  • 20. [Immunogenic and protective characteristics of recombinant Lassa virus NP protein].
    Ignat'ev GM
    Vopr Virusol; 2002; 47(2):28-31. PubMed ID: 12046464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.